Peritoneal cancer treatment with immunotherapy

Immunotherapy is a targeted treatment for peritoneal cancer that uses the body's immune system to attack cancer cells specifically. It is a more precise and potentially less toxic approach than traditional methods. Immunotherapy has shown positive results in treating peritoneal cancer, including advanced stages. Immunotherapy drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) help the immune system fight cancer cells better by blocking specific proteins in the cancer cells. As a result, it allows the immune system to recognize and destroy malignant cells more effectively. In peritoneal cancer, immunotherapy focuses on specific pathways involved in DNA repair. By targeting these pathways, the therapies exploit weaknesses in the cancer cells and help the immune system fight against peritoneal cancer. The treatment involves thorough examinations and consultations, diagnostic tests, and preparations for immunotherapy. The specific drugs used depend on the patient's case. Post-procedure care includes monitoring the patient's response, managing side effects, and providing supportive care. Immunotherapy for peritoneal cancer can be used alone or with other treatments like surgery, chemotherapy, etc. The benefits include improved disease control, increased survival rates, and symptom reduction, leading to a better quality of life for patients. Immune drugs are essential advancement in peritoneal cancer treatment, offering new hope and better outcomes.